ERBB2 and breast cancer: Then, to evaluate whether dual blockade of CD36 and HER2 can affect the tumor-initiating cell component of HER2 + resistant BC cells in vivo, engineered MDAMB361-shSCR and MDAMB36-shCD36 (1) cells were pretreated in vitro for 72 h with 0.45 μM lapatinib or DMSO (as a control) and were then injected into a m.f.p. of SCID mice (n = 9 × 105 cells/mouse).